Zimbabwe has rejected a significant American healthcare agreement valued at $367m (£272m) over five years due to the United States' insistence on confidential biological samples.
The decision became public after a internal memorandum dated December was leaked, indicating that President Emmerson Mnangagwa felt the agreement was "lopsided".
An official spokesman later explained that the United States was demanding access to genetic material for scientific study and profit while was unwilling to share the benefits from future treatments.
"We will now turn to the difficult and regrettable process of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had donated more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for continued negotiations to secure a agreement agreeable to both sides so the nation's vital HIV treatment initiative can proceed.
Wider Background
This rejection comes after a similar situation in neighbouring Kenya, where a court blocked a similar deal with the US following concerns were raised about the safety of citizens' medical information.
After returning to office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing government-to-government deals to boost transparency and accountability.
According to reports, 16 African countries have to date agreed to these new health pacts, constituting over $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration might have yielded significant advantages for the people of Zimbabwe, especially the 1.2 million currently receiving antiretroviral therapy through US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information indefinitely, without any corresponding assurance of access to any medical innovations – like new medicines or tests – that could result from that provided information," Mangwana explained.
"Effectively, our nation would supply the raw materials for scientific discovery with no certainty that the final treatments would be accessible to our citizens if a new disease outbreak emerge."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining systems previously established via the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential pandemics.
"This framework is designed to guarantee that when a country contributes its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
The government's concerns regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome further discussions with our American counterparts on how future collaboration might be arranged in a manner that respects the sovereignty and dignity of each country."
Medical Community Reaction
Medical experts stated it understood the government's concerns, but urged that negotiations must proceed considering a large portion of the country's HIV programmes were funded by international support.
"If specific concerns arise, including those involving information security or agreement terms, these can frequently be addressed through technical clarification and negotiated safeguards," it said.
The situation underscores the complex tensions between accepting vital foreign assistance and protecting local interests in an ever more data-driven world.